Jiangsu Hengrui’s SHR0302 Secures Clinical Trial Approval for GVHD Treatment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced the receipt of...
Drug
Sanofi’s VaxigripTetra Expands Influenza Vaccine Access to All Ages in China
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its tetravalent influenza virus split vaccine,...
AstraZeneca’s Nirsevimab on Track for Priority Review for RSV Prevention in Infants
The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN)...
Antengene Submits Market Approval Filing for Xpovio in Indonesia for Multiple Myeloma and Lymphoma
Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...
TYK Medicines Receives CDE Approval for CDK7 Inhibitor TY-2699a Clinical Study
Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug...
Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...
BeiGene’s Tislelizumab Secures First Approvals Outside China Mainland in Macau
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...
Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial
Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...
Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...
Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...
Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study
China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...
Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD
Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...
Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy
Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...
CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces
The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates...
Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...
Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review
China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901...
Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE
The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...
Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled...
CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China
The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...
Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA
Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...